Synopsys Completes Acquisition of Ansys
News Highlights:
Combines leaders in silicon design, IP and simulation and analysis to enable customers to rapidly innovate AI-powered products
Now positioned to win in an expanded $31 billion total addressable market (TAM) 1
Fast-tracking integrated technology roadmap, with first set of combined capabilities planned for the first half of 2026
SUNNYVALE, Calif., July 17, 2025 /CNW/ -- Synopsys (Nasdaq: SNPS) today announced the completion of its acquisition of Ansys. The transaction, which was announced on January 16, 2024, combines leaders in silicon design, IP and simulation and analysis to enable customers to rapidly innovate AI-powered products. Synopsys is now positioned to win in an expanded $31 billion total addressable market (TAM). 1
"Today marks a transformational milestone for Synopsys. For decades, Synopsys has been delivering breakthroughs in silicon design and IP that have fueled chip innovation," said president and CEO of Synopsys, Sassine Ghazi. "The increasing complexity of developing intelligent systems demands design solutions with a deeper integration of electronics and physics, enhanced by AI. With Ansys' leading system simulation and analysis solutions now part of Synopsys, we can maximize the capabilities of engineering teams broadly, igniting their innovation from silicon to systems."
Former Ansys president, CEO, and board member Ajei Gopal and former Ansys board member Ravi Vijayaraghavan are joining Synopsys' board of directors, effective immediately.
"For half a century, Ansys has enabled innovators across industries to push boundaries with the predictive power of simulation and analysis," said Gopal. "Our companies have a common culture, a successful longstanding partnership, and now a united mission to empower innovators to drive human advancement. I look forward to serving this mission as a member of the Synopsys board and expect a swift, successful integration."
Synopsys remains dedicated to helping engineers innovate, reduce time-to-market and costs, and improve product quality by delivering unprecedented insights into how their products will perform in the real world. And, united with Ansys, Synopsys can now deliver holistic system design solutions for customers in industries spanning semiconductors, high-tech, automotive, aerospace, industrial, and more.
Synopsys expects to deliver the first set of integrated capabilities in the first half of 2026 that fuse multiphysics across the full EDA stack, including for multi-die advanced packaging. The combined roadmap also includes integrated solutions to advance testing and virtualization of complex, intelligent systems for automotive and other industries.
This combination bolsters Synopsys' strong financial position with projected margin expansion and greater unlevered free cash flow generation, enabling rapid deleveraging over a period of two years. Ansys common stock will no longer be listed for trading on the NASDAQ stock market.
Other Resources
Video message from Sassine Ghazi
Synopsys Blog: 'Re-engineering Engineering from Silicon to Systems'
1
2023 TAM based on Synopsys management estimates
About Synopsys
Synopsys, Inc. (Nasdaq: SNPS) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. We deliver industry-leading silicon design, IP, simulation and analysis solutions, and design services. We partner closely with our customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at www.synopsys.com.
© 2025 Synopsys, Inc. All rights reserved. Synopsys, the Synopsys logo, and other Synopsys trademarks are available at https://www.synopsys.com/company/legal/trademarks-brands.html. Other company or product names may be trademarks of their respective owners.
Forward Looking Statements
This press release includes certain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements that relate to our expected future business and financial performance, the anticipated benefits of the transaction, the anticipated impact of the transaction on the combined business, and the expected synergies from the transaction. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions or the negatives of these words or other comparable terminology to convey uncertainty of future events or outcomes. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks, uncertainties and other factors that could cause actual future events to differ materially from the forward-looking statements in this communication, including, but not limited to: (i) our ability to maintain relationships with Synopsys' and Ansys' customers, suppliers and other business partners; (ii) the effect of the transaction on our operating results and business; (iii) our ability to implement plans, forecasts, expected financial performance and other expectations with respect to the combined business and realize the expected benefits/synergies as well as manage the scope and size of the combined company; (iv) unexpected costs, charges and expenses related to the integration; (v) our ability to successfully integrate Ansys' operations and product lines; (vi) difficulties in retaining and hiring key personnel and employees due to the integration; (vii) the diversion of management time on integration; (viii) our ability to manage significant indebtedness, including indebtedness incurred in connection with the transaction, and the need to generate sufficient cash flows to service and repay such debt; (ix) uncertainty in the macroeconomic and geopolitical environment and its potential impact on the semiconductor and electronics industries; (x) uncertainty in the growth of the semiconductor, electronics and artificial intelligence industries, (xi) the highly competitive industries we operate in; (xii) actions by the U.S. or foreign governments, such as the assessment of fines or the imposition of additional export restrictions or tariffs; (xiii) consolidation among our customers and within the industries in which we operate, as well as our dependence on a relatively small number of large customers; and (xiv) the evolving legal, regulatory and tax regimes under which we operate.
Our filings with the Securities and Exchange Commission, which you may obtain for free at its website at http://www.sec.gov, discuss some of the important risk factors that may affect our business, results of operations and financial condition. Actual results may vary from the estimates provided. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.
Editorial Contact
Cara Walker
Synopsys, Inc.
(650) 584-5000
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
2 hours ago
- Toronto Star
Aura Declares Dividend of US$0.33 Per Share and US$0.11 Per BDR Based on Q2 2025 Results, Resulting in a Dividend Yield of 7.4% in the LTM
ROAD TOWN, British Virgin Islands, Aug. 05, 2025 (GLOBE NEWSWIRE) — Aura Minerals Inc. (Nasdaq: AUGO) (TSX: ORA) (B3: AURA33) ('Aura' or the 'Company') announced today that the Company's Board of Directors (the 'Board') has declared and approved the payment of a dividend (the 'Dividend') of US$0.33 per common share (approximately US$ 27.32 million in total). This payment is above the minimum foreseen in the Company's Dividend Policy (the 'Dividend Policy'). Under the Dividend Policy, the Company may determine quarterly cash dividends in an aggregate amount equal to 20% of its reported Adjusted EBITDA3 for the relevant three months, less sustaining capital expenditures and exploration capital expenditures for the same period. The Dividend will be paid in US dollars on August 26, 2025, to shareholders of record as of the close of business on August 18, 2025 ('Record Date').
Globe and Mail
3 hours ago
- Globe and Mail
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
Key Points Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. 10 stocks we like better than Recursion Pharmaceuticals › Before market open on Tuesday, Recursion Pharmaceuticals (NASDAQ: RXRX) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers clearly didn't impress the market. The company's stock ended up closing the day almost 5% lower in price, a steeper fall than the 0.5% dip of the benchmark S&P 500 index. Second quarter: revenue rose, but net loss deepened For its second quarter, Recursion earned $19.2 million in revenue, which was up from the slightly more than $14.4 million in the same period of 2024. However, the clinical-stage biotech company's generally accepted accounting principles (GAAP) net loss deepened considerably, coming in at almost $172 million ($0.41) against the $97.5 million deficit in the year-ago period. Although analysts tracking the stock were collectively modeling a lower revenue figure of $15.4 million, their net loss estimate was considerably narrower, at $0.35 per share. Recursion, which targets cancer and rare disorders with its investigational drugs, provided an update on its pipeline. The most advanced of its programs, oncology drug REC-617, advanced into a phase 1/2 clinical trial in the first half of the year. Teaming up As a biotech without a product currently on pharmacy shelves, Recursion generates modest revenue largely from collaborations with large pharmaceutical companies. Among these well-known mainstays are Bayer and Merck. In the earnings release, it updated the status of several of these; an especially promising one now is a tie-up with Sanofi, which has the potential to produce more than $300 million in milestone payments. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Stock Market Today: Nvidia Slips Nearly 1% on Tariff Jitters Despite ARK Fund Confidence
Nvidia (NASDAQ: NVDA) declined 0.97% on Tuesday to close at $178.26, retreating modestly from recent highs as semiconductor stocks faced pressure amid fresh trade policy concerns. Trading volume came in at 152.2 million shares, about 21% below its average. Broader markets were also lower, with the S&P 500 down 0.49% and the Nasdaq Composite falling 0.65%. Traders reacted to signals that former President Donald Trump may soon propose increased tariffs on semiconductor imports in a bid to boost domestic manufacturing. Nvidia's peers were similarly under pressure. Advanced Micro Devices dropped 1.40%, while Broadcom lost 1.61%, extending a multi-day pullback across the chip sector. Despite the red close, institutional confidence in Nvidia remained intact. Cathie Wood's ARK Autonomous Technology & Robotics ETF and ARK Space Exploration & Innovation ETF disclosed purchases of 23,211 Nvidia shares -- a combined investment of roughly $4.2 million. Nvidia now makes up approximately 2.7% of each ETF. Looking ahead, analysts at Bank of America reiterated a $220 price target, citing resilient demand for Nvidia's Blackwell GPUs and continued strength in AI infrastructure spending. While shares are consolidating just below their record high, momentum remains strong heading into the next earnings cycle. Market data sourced from Google Finance and Yahoo! Finance on Tuesday, August 5, 2025. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Bank of America is an advertising partner of Motley Fool Money. Daily Stock News has no position in any of the stocks mentioned. This article was generated with GPT-4o, OpenAI's large-scale language generation model and has been reviewed by The Motley Fool's AI quality control systems. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy.
